Biohaven Pharmaceutical Holding Company Ltd. (BHVN +4.8%) is up on below-average volume in response the publication of Phase 3 results on migraine med Zydis (rimegepant) orally dissolving tablet in The Lancet.
The data showed that treatment with Zydis statistically significantly increased freedom from pain and freedom from the most-bothersome symptom within two hours of a single dose compared to placebo. It demonstrated superiority to placebo on 21 prespecified endpoints.
All three Phase 3 studies were successful.
The company filed a U.S. marketing application last quarter with a priority review voucher that permits a six-month review clock.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.